Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsArizona Complete Health ETRA Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedArizona Complete HealthPolicy AZ.CP.PHAR.1012

    Endothelin Receptor Antagonists (ETRA)

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PHAR.1012 alerts

    Get alerted when Policy AZ.CP.PHAR.1012 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity requirements for ambrisentan (Letairis), bosentan (Tracleer), and macitentan (Opsumit) for Arizona Medicaid members, including initial and continued therapy, preferred-product requirements, step therapy, documentation, and non-covered indications.

    Policy Summary
    PayerArizona Complete Health
    PolicyEndothelin Receptor Antagonists (ETRA)
    Policy CodePolicy AZ.CP.PHAR.1012
    Change TypeModified
    Effective DateAug 18, 2019
    Last ReviewFeb 1, 2021
    Next Review DateN/A
    Key ActionSubmit documentation supporting that all applicable approval criteria are met for ambrisentan, bosentan, or macitentan prior authorization requests.
    SourceLink
    POLICY UPDATE CHANGES

    A maximum quantity per day was added.

    Wording was added to specify that the criteria also apply to Care1st.

    3ETRA drugs requiring prior authorization
    6 monthsInitial approval duration
    12 monthsContinued-therapy approval duration
    >25 mm Hg

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Mean pulmonary arterial pressure threshold
    WHO Group 1PAH classification
    10 mg/dayMaximum listed dose

    Coverage Criteria

    Initial therapy

    Covered for pulmonary arterial hypertension when ALL of the following are met:

    Initial PAH approval

    • Clinical diagnosis and specialist: The member has a diagnosis of pulmonary arterial hypertension, and the medication is prescribed by or in consultation with a cardiologist or pulmonologist.
    • Hemodynamic confirmation: Right heart catheterization results show a mean pulmonary arterial pressure greater than 25 mm Hg.>25 mm Hg
    • Product selection

      • Requests for Letairis or Tracleer are for the brand-only product.
      • For Opsumit requests, ONE of the following applies

        • The member has failed Letairis and Tracleer.
        • Letairis or Tracleer is contraindicated.
        • The member experienced clinically significant adverse effects from Letairis or Tracleer.
    • Calcium-channel-blocker therapy

      • ONE of the following applies

        • The member has failed a calcium channel blocker.
        • Acute vasodilator testing produced an inadequate response or was contraindicated.
        • A calcium channel blocker is contraindicated or caused clinically significant adverse effects.
    • Dose limit: The requested dose does not exceed the FDA-approved maximum recommended dose.FDA-approved maximum recommended dose

    Continued therapy

    Covered for continued pulmonary arterial hypertension therapy when ALL of the following are met:

    Continuation PAH approval

    • Existing therapy qualification

      • The member is currently receiving the medication through the Centene benefit.
      • The member previously met all initial approval criteria.
    • Clinical response: The member is responding positively to therapy.
    • Dose limit for increases: If the request is for a dose increase, the new dose does not exceed the FDA-approved maximum recommended dose.FDA-approved maximum recommended dose

    Non-FDA-approved indications

    Not covered unless the applicable off-label policy supports the indication:

    Non-authorized indications: A non-FDA-approved indication that is not addressed by this policy is not covered unless sufficient documentation of efficacy and safety supports coverage under the applicable off-label use policy, AZ.CP.PMN.53, for Arizona Medicaid.

    Non-FDA-approved indications not addressed in this policy are not covered unless sufficient documentation of efficacy and safety supports coverage under the applicable Arizona Medicaid off-label use policy, AZ.CP.PMN.53.

    Clinical Thresholds

    Mean pulmonary arterial pressure
    Required threshold> 25 mm Hg

    Provider Requirements and Decision Risks

    Prior Authorization

    ETRA Prior Authorization Required

    Prior authorization is required for all endothelin receptor antagonists (ETRAs): ambrisentan (Letairis), bosentan (Tracleer), and macitentan (Opsumit). Letairis and Tracleer are AHCCCS preferred brand-only products; generic ambrisentan, generic bosentan, and Opsumit are non-preferred.

    • PA-required agents: ambrisentan, bosentan, and macitentan.
    • Preferred products: Letairis (brand only) and Tracleer (brand only).
    • Non-preferred products: generic ambrisentan, generic bosentan, and Opsumit.
    Documentation Required

    Initial Approval: PAH Criteria

    Initial approval for pulmonary arterial hypertension (PAH) requires all listed clinical, prescriber, diagnostic, product-selection, step-therapy, and dosing criteria. Initial approval is granted for 6 months.

    Clinical Background

    Endothelin receptor antagonists (ETRAs) are used to treat pulmonary arterial hypertension (PAH), primarily WHO Group 1 disease, by reducing pulmonary arterial pressure through vasodilation. This policy addresses the covered products Letairis (ambrisentan), Tracleer (bosentan), and Opsumit (macitentan). Letairis and Tracleer are indicated to improve exercise ability and reduce or delay clinical worsening, while Opsumit is indicated to delay disease progression and reduce hospitalization for PAH.

    Definitions and Functional Classes

    Abbreviation
    FCFunctional class
    Abbreviation
    PAHPulmonary arterial hypertension
    Abbreviation
    FDAFood and Drug Administration
    Abbreviation
    PHPulmonary hypertension

    Initial PAH Approval

    PAH initial approval

    Initial PAH approval requires ALL of the following:

    Initial PAH therapy

    • Clinical diagnosis and specialist: The member has a diagnosis of pulmonary arterial hypertension, and the medication is prescribed by or in consultation with a cardiologist or pulmonologist.
    • Hemodynamic confirmation: Right heart catheterization results show a mean pulmonary arterial pressure greater than 25 mm Hg.>25 mm Hg
    • Product selection

      • Requests for Letairis or Tracleer are for the brand-only product.

    Continued PAH Therapy

    PAH continuation

    Continued therapy requires ALL of the following:

    Continuation therapy

    • Existing therapy qualification

      • The member is currently receiving the medication through the Centene benefit.
      • The member previously met all initial approval criteria.
    • Clinical response: The member is responding positively to therapy.
    • Dose limit for increases: If the request is for a dose increase, the new dose does not exceed the FDA-approved maximum recommended dose.

    Required Treatment Trials

    StepMedicationRequirementExceptions
    1Opsumit (macitentan)Failure of both Letairis and Tracleer is required before Opsumit approval.Either Letairis or Tracleer is contraindicated, or the member experienced clinically significant adverse effects from either drug.
    StepTherapy requirementExceptionsListed alternatives
    2Failure of a calcium channel blocker is required.An inadequate response or contraindication to acute vasodilator testing; or the calcium channel blocker is contraindicated or caused clinically significant adverse effects.Nifedipine (maximum 240 mg/day); diltiazem (maximum 960 mg/day); or amlodipine (maximum 30 mg/day).

    Maximum Daily Doses

    Letairis (ambrisentan)
    Maximum dose10 mg per day
    Opsumit (macitentan)
    Maximum dose10 mg per day
    Policy Summary
    PayerArizona Complete Health
    PolicyEndothelin Receptor Antagonists (ETRA)
    Policy CodePolicy AZ.CP.PHAR.1012
    Change TypeModified
    Effective DateAug 18, 2019
    Last ReviewFeb 1, 2021
    Next Review DateN/A
    Key ActionSubmit documentation supporting that all applicable approval criteria are met for ambrisentan, bosentan, or macitentan prior authorization requests.
    SourceLink
    On This Page
    Coverage CriteriaClinical ThresholdsProvider Requirements and Decision RisksClinical BackgroundDefinitions and Functional ClassesInitial PAH ApprovalContinued PAH TherapyRequired Treatment TrialsMaximum Daily Doses
  1. Document a diagnosis of PAH.
  2. The medication must be prescribed by, or used in consultation with, a cardiologist or pulmonologist.
  3. Submit right heart catheterization results showing mean pulmonary arterial pressure (PAP) greater than 25 mm Hg.
  4. Requests for Letairis or Tracleer must be for the brand-only product.
  5. For Opsumit, the member must have failed both Letairis and Tracleer, unless either is contraindicated or causes clinically significant adverse effects.
  6. The member must have failed a calcium channel blocker, unless there is an inadequate response or contraindication to acute vasodilator testing, or a contraindication or clinically significant adverse effect from a calcium channel blocker.
  7. The requested dose must not exceed the FDA-approved maximum recommended dose.
  8. Step Therapy

    Preferred ETRA Trial

    For Opsumit requests, document failure of both preferred ETRAs—Letairis and Tracleer—before approval. The trial requirement may be bypassed when either product is contraindicated or produces clinically significant adverse effects.

    • Required sequence: fail Letairis and Tracleer.
    • Exception: applicable contraindication to Letairis or Tracleer.
    • Exception: clinically significant adverse effect from Letairis or Tracleer.
    Step Therapy

    Calcium Channel Blocker Trial

    Initial therapy requires failure of a calcium channel blocker unless an allowed acute vasodilator-testing exception or calcium-channel-blocker exception applies.

    • Trial the applicable calcium channel blocker alternative, such as nifedipine, diltiazem, or amlodipine, unless an exception applies.
    • Exception: inadequate response or contraindication to acute vasodilator testing.
    • Exception: contraindication or clinically significant adverse effects to a calcium channel blocker.
    Documentation Required

    Clinical Documentation Required

    Submit office chart notes, laboratory results, or other clinical information sufficient to demonstrate that the member meets all applicable approval criteria.

    • Documentation should support the diagnosis, specialist involvement, diagnostic findings, treatment history, contraindications or adverse effects when used as exceptions, therapeutic response, and requested dosing.
    Documentation Required

    Initial Request Support

    For an initial request, include documentation supporting PAH, specialist prescribing or consultation, right heart catheterization, and each applicable product-selection, step-therapy, exception, and dosing requirement.

    • PAH diagnosis.
    • Cardiologist or pulmonologist prescription or consultation.
    • Right heart catheterization results with mean PAP > 25 mm Hg.
    • Brand-only selection for Letairis or Tracleer, when requested.
    • Documented failure of preferred ETRAs for Opsumit, or the applicable contraindication/adverse-effect exception.
    • Calcium channel blocker failure or an applicable acute vasodilator-testing or calcium-channel-blocker exception.
    • Requested dose at or below the FDA-approved maximum.
    Denial Risk

    Failure to Meet Initial Approval Criteria

    The request may be denied when the member does not have documented PAH, lacks cardiologist or pulmonologist prescribing or consultation, or fails any other required initial-approval criterion.

    • Risk of denial for missing or unsupported PAH diagnosis.
    • Risk of denial without specialist prescribing or consultation.
    • Risk of denial without qualifying right heart catheterization results.
    • Risk of denial when product selection, preferred-ETRA trial, calcium-channel-blocker trial or exception, or FDA maximum-dose requirements are not met.
    Denial Risk

    Unapproved or Unsupported Indication

    For other diagnoses or indications, consult the applicable off-label use policy. Non-FDA-approved indications not addressed by this policy are not authorized unless sufficient efficacy and safety documentation supports coverage under the applicable off-label policy.

    • For Arizona Medicaid, refer to off-label use policy AZ.CP.PMN.53.
    • Insufficient efficacy or safety documentation for an unapproved indication creates a denial risk.
    Documentation Required

    Continuation Approval

    Continuation approval requires that the member is currently receiving the medication through a Centene benefit or previously met all initial approval criteria, and that the member is responding positively to therapy. Continuation approval is granted for 12 months.

    • Current therapy is covered through a Centene benefit, or the member previously satisfied all initial approval criteria.
    • Document a positive response to therapy.
    • For a dose increase, the new dose must not exceed the FDA-approved maximum recommended dose.
    Denial Risk

    Failure to Meet Continuation Criteria

    Continuation may be denied when benefit coverage or prior satisfaction of initial criteria cannot be established, positive response is not documented, or a dose increase exceeds the FDA-approved maximum recommended dose.

    • Risk of denial without current Centene benefit coverage or evidence that initial criteria were previously met.
    • Risk of denial without documented positive response to therapy.
    • Risk of denial for a dose increase above the FDA-approved maximum recommended dose.
    Abbreviation
    NYHANew York Heart Association
    Abbreviation
    WHOWorld Health Organization
    Abbreviation
    RHCRight heart catheterization
    Abbreviation
    PAPPulmonary arterial pressure
    WHO Functional Class I
    Status at restComfortable at rest.
    Physical activity toleranceNo limitation.
    Activity symptomsOrdinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope.
    WHO Functional Class II
    Status at restComfortable at rest with slight limitation.
    Activity symptomsOrdinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope.
    WHO Functional Class III
    Status at restComfortable at rest with marked limitation.
    Activity symptomsLess-than-ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope.
    WHO Functional Class IV
    Symptoms at restDyspnea or fatigue may be present at rest.
    Physical activityUnable to carry out any physical activity without discomfort; discomfort is increased by any activity.
    Heart failureSigns of right-heart failure.
  9. For Opsumit requests, ONE of the following applies

    • The member has failed Letairis and Tracleer.
    • Letairis or Tracleer is contraindicated.
    • The member experienced clinically significant adverse effects from Letairis or Tracleer.
  10. Calcium-channel-blocker therapy

    • ONE of the following applies

      • The member has failed a calcium channel blocker.
      • Acute vasodilator testing produced an inadequate response or was contraindicated.
      • A calcium channel blocker is contraindicated or caused clinically significant adverse effects.
  11. Dose limit: The requested dose does not exceed the FDA-approved maximum recommended dose.FDA-approved maximum recommended dose
  12. FDA-approved maximum recommended dose